Replimune Group, Inc. (REPL) - Stock Analysis
Last updated: Jun 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative biotech momentum candidate: stock rose about 113% over 21 trading days, helped by 2026-05-29 FDA alignment on a path forward for RP1 plus nivolumab BLA resubmission/reconsideration and ASCO clinical updates on 2026-05-30 and 2026-05-31.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Heavy Cash Burn ⢠Funding Dependence REPL remains highly liquid and debt-manageable, but zero revenue, persistent operating and free-cash-flow losses, and dependence on financing make it a cash-runway story rather than an earnings story.
Price Behavior
Key Price Behavior Insights: ⢠Breakout surge ⢠Higher highs ⢠Overextended move Support Level: $8.87-$9.00 Resistance Level: $9.98-$10.00 REPL has surged strongly over the last month in a breakout-driven uptrend, but the move looks extended and may need a pause unless it holds support near $8.87-$9.00.
Sentiment & News
Key News Insights: ⢠FDA reset ⢠Legal scrutiny ⢠ASCO data Replimune shifted from securities-law scrutiny and repeated FDA setbacks to a sharp rebound after aligning with the FDA on RP1 resubmission and reporting encouraging ASCO clinical data.
AI Summary
REPL has shifted from a near-term FDA dead-end to a narrow resubmission/de-risking story, but after the sharp rally the stock now trades ahead of proof while heavy cash burn and dilution risk mean investors should treat it as a catalyst-driven trade rather than a fundamentals-backed compounder.
Description
Replimune Group, Inc. is a biotechnology company developing oncolytic immuno-gene therapies for cancer using its proprietary Immunotherapy platform. Its lead candidate, RP1, is a selectively replicating herpes simplex virus 1 therapy being evaluated in clinical trials for solid tumors and cutaneous squamous cell carcinoma, alongside earlier-stage programs including RP2 and RP3. The company was founded in 2015 and is based in Woburn, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 10 | Jun 17 | REPL | Replimune Group, Inc. | Speculative biotech momentum candidate: stock rose about 113% over 21 trading days, helped by 2026-05-29 FDA alignment on a path forward for RP1 plus nivolumab BLA resubmission/reconsideration and ASCO clinical updates on 2026-05-30 and 2026-05-31. | Active | +4.8% |